31results about How to "Efficient synergy" patented technology

The invention discloses a medicine for treating esophageal squamous cell carcinoma and a preparation method thereof. The drug is the combined drug of arctigenin, salvia miltiorrhiza, and Chuanqiong, which shows a significant inhibitory effect on human esophageal squamous cell carcinoma at a certain ratio. The milk system can form the drug into a stable and uniform solution, and the in vivo experiments have proved that it has a high and significant therapeutic effect on esophageal squamous cell carcinoma.

The invention discloses a multi-industrial-manipulator controller based on a double-layer CPG (central pattern generator). A structure similar to a layered neural network, which the ganglion controlling activities of invertebrates has and which a central nervous system controlling activities of vertebrates has, is adopted, features of a multi-industrial-manipulator control system and those of a single industrial manipulator are combined, and collective coordination and information interaction of multiple industrial manipulators are efficiently synergic. Flexible joints and a rich sensor system are adopted, information utilization rate of the multiple industrial manipulators is increased, and the joints of the industrial manipulators are effectively controlled, so that the system has high reliability and stability. The sensor system has the ability of autokinetic movement while the industrial-manipulator is enabled to have sufficient dynamic performance and degree of freedom. The multi-industrial-manipulator controller is composed of a phase coordination layer and a motion pattern generation layer; the phase coordination layer allows phase sequence locking for each industrial manipulator; the motion pattern generation layer allows trajectory planning and attitude adjustment for each industrial manipulator.

The invention discloses an active-targeting amphiphilic polypeptide composite nano-micelle prodrug, its preparation and application, and belongs to the technical field of biomedicine. The composite nanomicelle prodrug of the present invention is obtained by co-assembling a negatively charged first polypeptide and a positively charged second polypeptide through electrostatic interaction and hydrophilic-hydrophobic interaction; the first polypeptide is Lys-AA m ‑Gly‑Arg‑Gly‑Asp‑Ser, wherein AA is aspartic acid or glutamic acid, m is 1, 2, 3 or 4; the second polypeptide is Cys‑BB n , wherein BB is lysine, arginine or histidine, and the value of n is 1, 2, 3 or 4; the amino group at the N-terminal of the first polypeptide is connected to a hydrophobic alkyl chain, and the lysine side of the first polypeptide is The amino group of the chain is connected with the fluorescent molecule; the cysteine ​​in the second polypeptide is covalently connected with the anti-tumor drug through the sulfhydryl group. The nanocomposite micelles can actively target tumor cells and disassemble in response to the slightly acidic environment of the tumor to form small-sized micelles with a size of 20-30nm, which is conducive to the deep delivery of polypeptide anti-tumor prodrugs in tumor sites.